Hogan Lovells advises EyePoint on its US$150 million follow-on public offering of equity securities

EyePoint is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases.

EyePoint announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of US$12 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 1,500,000 shares of its common stock at a price to the public of US$11.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the US$0.001 per share exercise price for each such pre-funded warrant.

The aggregate gross proceeds from this offering were approximately US$150 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. More information can be found here.

The Hogan Lovells deal team was led by partner Stephen Nicolai (Philadelphia), associates Kayvon Paul and Athira Sivan (both Philadelphia), and law clerk Diane Shin (New York).

This comes on the heels of our previous work with EyePoint. In November 2024, we advised EyePoint on its US$161 million follow-on public offering of common stock. Additionally, in December 2023, we advised the company on its US$230 million follow-on public offering of common stock.